Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Boehringer Ingelheim
Dow
Colorcon
AstraZeneca
Johnson and Johnson

Last Updated: January 21, 2022

DrugPatentWatch Database Preview

Details for Patent: 7,456,254


Email this page to a colleague

« Back to Dashboard

Summary for Patent: 7,456,254
Title:Polymer-based sustained release device
Abstract: This invention relates to compositions for the sustained release of biologically active polypeptides, and methods of forming and using said compositions, for the sustained release of biologically active polypeptides. The sustained release compositions of this invention comprise a biocompatible polymer having dispersed therein, a biologically active polypeptide and a sugar.
Inventor(s): Wright; Steven G. (Madeira, OH), Christenson; Troy (Mason, OH), Yeah; Thean Y. (Foxboro, MA), Rickey; Michael E. (Morrow, OH), Hotz; Joyce M. (Cincinnati, OH), Kumar; Rajesh (Marlborough, MA), Costantino; Henry R. (Woodinville, WA)
Assignee: Alkermes, Inc. (Cambridge, MA)
Application Number:11/104,877
Patent Claim Types:
see list of patent claims
Composition; Use;

Drugs Protected by US Patent 7,456,254

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Astrazeneca Ab FARXIGA dapagliflozin TABLET;ORAL 202293-001 Jan 8, 2014 RX Yes No ⤷  Try it Free ⤷  Try it Free Y TREATMENT OF TYPE 2 DIABETES MELLITUS IN COMBINATION WITH EXENATIDE ⤷  Try it Free
Astrazeneca Ab FARXIGA dapagliflozin TABLET;ORAL 202293-002 Jan 8, 2014 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y TREATMENT OF TYPE 2 DIABETES MELLITUS IN COMBINATION WITH EXENATIDE ⤷  Try it Free
Astrazeneca Ab BYDUREON exenatide synthetic FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS 022200-001 Jan 27, 2012 DISCN Yes No ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
Astrazeneca Ab BYDUREON PEN exenatide synthetic FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS 022200-002 Feb 28, 2014 DISCN Yes No ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
Astrazeneca Ab BYDUREON BCISE exenatide synthetic SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS 209210-001 Oct 20, 2017 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 7,456,254

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2005235100 ⤷  Try it Free
Brazil PI0509946 ⤷  Try it Free
Canada 2560874 ⤷  Try it Free
Canada 2798552 ⤷  Try it Free
China 101065116 ⤷  Try it Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Mallinckrodt
Boehringer Ingelheim
Express Scripts
Medtronic
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.